BEVERLY, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, responds to the latest defamatory article published today on Seeking Alpha by the short-selling anonymous author going only by the name Mako Research.
As with Mako’s prior article on Cellceutix, the non-credible criminal author makes countless unfounded, wild allegations about the Company. The purpose of the iniquitous writings of Mako is to scare shareholders and drive CTIX stock lower for the profit of the author and all organizations collaborating in the illegal and manipulative market activity often called, “short and distort.”
The original article served as the foundation for a class action lawsuit, which was dismissed by the court with prejudice, as there was no truth in Mako’s so-called “research.” The entire legal case discrediting Mako can be viewed at:
http://ia601507.us.archive.org/4/items/gov.uscourts.nysd.447344/gov.uscourts.nysd.447344.docket.html.
“Mako is a pawn in an organized criminal enterprise that profits tremendously from this type of fake news that Seeking Alpha relishes publishing because it drives web traffic. There’s a reason that the courts have ruled that Seeking Alpha is not a credible news source,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “We will continue to gather information on Mako and his co-conspirators.”